Table 1. Characteristics of the 119,379 patients with cancer included in the study between 2005 and 2014, based on specified cancer sites.
| Cancer site | Patients, n (%) | Males, n (%) | Age | CCI 1–2, | CCI >2, | Metastases at diagnosis, | Sepsis within 1 year, | Time of sepsis (days) |
|---|---|---|---|---|---|---|---|---|
| (years, IQR) | n (%) | n (%) | n (%) | n (%) | ||||
| Bladder | 2212 (1.9%) | 1728 (78.1%) | 58 (54–61) | 702 (32%) | 88 (4%) | 14 (0.6%) | 64 (3%) | 189 (79–246) |
| Bone | 239 (0.2%) | 138 (57.7%) | 55 (49–59) | 59 (25%) | 9 (4%) | 13 (5%) | 10 (4%) | 152 (84–230) |
| Brain | 596 (0.5%) | 336 (56.4%) | 54 (48–59) | 164 (28%) | 23 (4%) | 12 (2%) | 27 (5%) | 102 (78–139) |
| Breast | 33420 (28%) | 235 (0.7%) | 53 (47–58) | 6694 (20%) | 424 (1%) | 1349 (4%) | 400 (1%) | 118 (78–179) |
| Colorectal | 10589 (8.9%) | 5650 (53.4%) | 55 (50–59) | 2751 (26%) | 296 (3%) | 1345 (13%) | 387 (4%) | 130 (61–230) |
| Connective / soft tissue | 402 (0.3%) | 214 (53.2%) | 54 (48–59) | 110 (27%) | 16 (4%) | 24 (6%) | 21 (5%) | 158 (98–247) |
| Ear / nose | 103 (0.1%) | 69 (67.0%) | 54 (48–58) | 18 (18%) | 3 (3%) | 1 (1%) | 5 (5%) | 161 (103–182) |
| Esophagus | 1379 (1.2%) | 1162 (84.3%) | 57 (53–61) | 477 (35%) | 55 (4%) | 44 (3%) | 111 (8%) | 139 (82–222) |
| Hepatobiliary | 1505 (1.3%) | 919 (61.1%) | 57 (53–60) | 750 (50%) | 323 (2%) | 114 (8%) | 165 (11%) | 129 (59–201) |
| Hodgkin lymphoma | 759 (0.6%) | 453 (59.7%) | 50 (45–56) | 199 (26%) | 45 (6%) | N/A | 35 (5%) | 123 (52–198) |
| Kidney | 576 (0.5%) | 395 (68.6%) | 57 (52–60) | 214 (37%) | 30 (5%) | 83 (14%) | 28 (5%) | 112 (45–189) |
| Larynx | 450 (0.4%) | 342 (76.0%) | 57 (53–60) | 154 (34%) | 28 (6%) | 17 (4%) | 17 (4%) | 109 (93–250) |
| Lung | 7839 (6.6%) | 4032 (51.4%) | 58 (53–61) | 3726 (48%) | 487 (6%) | 1016 (13%) | 404 (5%) | 121 (57–218) |
| Lymph nodes metastases,unspecified | 2207 (1.8%) | 898 (40.7%) | 55 (50–59) | 629 (29%) | 61 (3%) | N/A | 63 (3%) | 113 (76–184) |
| Lymphoid leukemia | 715 (0.6%) | 454 (63.5%) | 55 (49–59) | 206 (29%) | 23 (3%) | N/A | 74 (10%) | 131 (55–217) |
| Melanoma | 499 (0.4%) | 290 (58.1%) | 54 (48–59) | 109 (22%) | 12 (2%) | 13 (3%) | 6 (1%) | 35 (27–86) |
| Mouth / pharynx | 1730 (1.4%) | 1394 (80.6%) | 56 (51–60) | 453 (26%) | 61 (4%) | 139 (8%) | 71 (4%) | 105 (66–204) |
| Multiple myeloma | 1746 (1.5%) | 984 (56.4%) | 56 (51–60) | 622 (36%) | 158 (9%) | N/A | 127 (7%) | 144 (77–220) |
| Myeloid leukemia | 1033 (0.9%) | 546 (52.9%) | 54 (48–60) | 325 (32%) | 34 (3%) | N/A | 189 (18%) | 89 (23–172) |
| Neuroendocrine | 215 (0.2%) | 108 (50.2%) | 55 (50–59) | 88 (41%) | 9 (4%) | 24 (11%) | 11 (5%) | 85 (52–166) |
| Non Hodgkin lymphoma | 5224 (4.4%) | 3001 (57.4%) | 55 (49–59) | 1590 (30%) | 278 (5%) | N/A | 269 (5%) | 95 (44–179) |
| Ovary | 2896 (2.4%) | 10 (0.3%) | 55 (49–59) | 700 (24%) | 60 (2%) | 723 (25%) | 90 (3%) | 94 (37–176) |
| Pancreas | 1829 (1.5%) | 1009 (55.2%) | 57 (53–61) | 859 (47%) | 116 (6%) | 331 (18%) | 201 (11%) | 118 (50–213) |
| Prostate | 6186 (5.2%) | 6179 (99.9%) | 59 (56–62) | 1796 (29%) | 230 (4%) | 60 (1%) | 56 (1%) | 94 (12–182) |
| Respiratory / GI metastases | 2112 (1.8%) | 930 (44.0%) | 57 (51–60) | 902 (43%) | 101 (5%) | N/A | 158 (7%) | 105 (49–219) |
| Retroperitoneum / peritoneum | 285 (0.2%) | 61 (21.4%) | 57 (51–60) | 87 (31%) | 6 (2%) | 52 (18%) | 17 (6%) | 93 (32–229) |
| Small intestine | 281 (0.2%) | 156 (55.5%) | 55 (49–59) | 107 (38%) | 13 (5%) | 54 (19%) | 24 (9%) | 133 (36–225) |
| Stomach | 1127 (0.9%) | 774 (68.7%) | 56 (50–60) | 424 (38%) | 58 (5%) | 122 (11%) | 90 (8%) | 168 (99–252) |
| Testis | 281 (0.2%) | 280 (99.6%) | 47 (43–52) | 59 (21%) | 9 (3%) | 14 (5%) | 7 (2%) | 143 (98–174) |
| Thymus/heart/mediastinum | 169 (0.1%) | 90 (53.3%) | 55 (49–59) | 70 (41%) | 8 (5%) | 14 (8%) | 12 (7%) | 87 (63–193) |
| Thyroid | 202 (0.2%) | 68 (33.7%) | 54 (48–58) | 82 (41%) | 6 (3%) | 7 (3%) | 4 (2%) | 111 (89–160) |
| Uterus | 3492 (2.9%) | 7 (0.2%) | 56 (50–60) | 933 (27%) | 54 (2%) | 167 (5%) | 113 (3%) | 136 (72–262) |
CCI: Charlson comorbidity index.